Presenter: Tanya O'Brien, BSc. Pharm

Learning Objectives:

1. Describe the mechanism of action of Sodium-glucose transport protein 2 (SGLT2) inhibitors.
2. State the evidence for SGLT2 inhibitors in Cardiovascular (CV) patients.
3. Identify the pathophysiology of euglycemic diabetic ketoacidosis (DKA) with SGLT2 inhibitors.
4. Apply various health agency's recommendations for SGLT2 inhibitors to patients in the hospital setting.
5. Illustrate some cases of eDKA at Eastern Health and apply various health agency's recommendations for SGLT2 inhibitors in the hospital setting.
6. Summarize appropriate management of hospitalized patients on SGLT2 inhibitors

Register here

Save the date

2022 Spring Education Session will be 10:00am - 3:00pm on June 11th, 2022! Available both online and in person in Moncton, and there will be an optional dinner that evening! (Location TBA). Registration will be online and will be sent via email early next week

Save the date

Pharmacy Residency Application System open to applicants

Save the date

Pharmacy Residency Application Matching System closes to applicants